by newerapr | Jun 15, 2023 | Press Release
IRVINE, Calif., – June 15, 2023 – Dynabook Americas, Inc., a leading provider of professional-grade laptops, today introduced its refreshed ultralight Portégé® X30L-K which includes the new hybrid-architecture 13th Gen Intel® Core™ P-Series 28W processors.
Weighing a mere 904 grams1, this professional grade laptop is configurable with 14 core CPUs, up to 32GB of LPDDR5 memory, ultra-fast SSD, Wi-Fi 6E and choice of a vivid IGZO or multitouch 13.3-inch displays driven by Intel Iris® Xegraphics, the Portégé X30L-K delivers uncompromising performance all day long.
The Portégé X30L-K comes standard with Windows 11 Pro to provide enhanced productivity features that deliver users a more personalized and intuitive user experience than previous generations of the operating system. The Portégé X30L-K is among the most secure laptops in the world and meets Microsoft’s strict Secured-core PC requirements and addresses the security and manageability challenges posed by the accelerated shift towards flexible working patterns.
Dynabook’s proprietary BIOS offers another extensive security layer to mitigate BIOS-level security threats, while numerous integrated features like Trusted Platform Module (TPM) 2.0, enterprise-grade encryption and optional Windows Hello fingerprint and face authentication help provide unrelenting protection against data, device and identify threats.
Designed for uncompromising portability, the Portégé X30L-K incorporates a durable, magnesium alloy chassis engineered to meet the rigorous MIL-STD-810G standards for endurance and durability. This hyper-light laptop is well-equipped for productivity and collaboration, through a variety of common ports, full size, backlit keyboard, dual pointing devices, HD webcam with privacy shutter, dual microphones, DTS® audio system and more.
Backed by Dynabook’s proven reliability and industry-leading +Care Service® Warranty2 with On-site the Portégé X30L-K from Dynabook will provide years of worry-free reliability. Featured SKUs are backed by three years of coverage while customized configurations are backed by four years. With additional access to an extensive service and support network, Dynabook +Care Service warranties help businesses minimize downtime and reduce IT costs.
The Portégé X30L-K is completely customizable and available via the company’s network of resellers or at us.dynabook.com. MSRP pricing will start at $1,379.99 for the Portégé X30L-K and all will include three years of Dynabook’s +Care Service Warranty with On-site.
Click here for the Dynabook Portégé X30L-K press kit.
Connect Online
Visit our website for the latest product details and specifications. Connect with us on our social media channels: LinkedInand Twitter.
About Dynabook Americas, Inc. (formerly Toshiba America Client Solutions, Inc.)
Headquartered in Irvine, Calif., Dynabook Americas, Inc., provides a diverse portfolio of enterprise-grade hardware and software offerings, including awarding-winning mobile computers, innovative wearable devices, augmented reality applications and security solutions. Dynabook designs, engineers, and manufactures its offerings in its own-operated facilities to ensure quality and reliability. Dynabook Americas is an independent operating company wholly owned by Dynabook, Inc., of Japan, a wholly owned company of Sharp Corporation. For more information on Dynabook Americas, visit https://us.dynabook.com/.
About Dynabook Inc. (formerly Toshiba Client Solutions Co., Ltd.)
For over 30 years, Dynabook laptops and technologies have set the standard for innovation, quality, and reliability. Now wholly owned by Sharp Corporation, Dynabook Inc., continues that tradition by delivering rich value and services that support our partners and customers in achieving their goals.
- Weight may vary depending on product configuration, vendor components, manufacturing variability and options selected.
- +Care Service Warranty with On-Site. Dynabook’s standard limited warranty terms and limitations apply. Visit https://support.dynabook.com/warranty for details.
© 2023 Dynabook Americas, Inc. Dynabook is a trademark of Dynabook Inc. All other product, service and company names are trademarks, registered trademarks, or service marks of their respective owners. Information including without limitation product prices, specifications, availability, content of services, and contact information is subject to change without notice. All rig
by newerapr | Jun 9, 2023 | Press Release
Madrid and Irvine, Calif., June 9, 2023 – TAE Life Sciences, a pioneering company in the field of cancer treatment, announces its participation in the 61st annual Particle Therapy Co-Operative Group (PTCOG) conference in Madrid, Spain. The event, held from June 10 – 16, 2023, will bring together leading experts, researchers, and organizations dedicated to advancing particle therapy in cancer treatment. TAE Life Sciences will be actively engaged in the conference, sharing scientific breakthroughs via oral and poster presentations, as well as co-hosting a symposium on Boron Neutron Capture Therapy (BNCT).
The co-hosted symposium, titled “The Current Status and Future of Accelerator-based BNCT – Advancement in hospital Neutron Sources and New Targeted Boron Drugs,” takes place the evening of June 13 at 18:30. During this presentation, Dr. Chad Lee, Director of Clinical Development at TAE Life Sciences will shed light on the company’s latest Alphabeam™ BNCT system and drug developments, as well as update attendees on treatment models for difficult-to-treat cancers, like head and neck, melanoma, glioblastoma multiforme (GBM), lung, and breast.
Kendall Morrison, Chief Science Officer at TAE Life Sciences, will deliver a compelling presentation entitled, “Development of Novel Targeted Boronated Small Molecule Drugs for BNCT and comparison with BPA in Neutron Irradiation Experiments,” during the BNCT Biology session on June 15 at 10:30. Morrison will discuss the breakthrough work conducted by TAE Life Sciences in developing targeted boronated small molecule drugs as alternatives to 4-boronophenylalanine (BPA). These new drugs aim to overcome limitations associated with BPA and BNCT. Morrison’s presentation will also explore the correlation between boron concentrations in tumors and the expression of the LAT-1 transporter.
“Our extensive research has found these novel small molecule compounds to exhibit remarkable solubility, cellular uptake, and retention, while also offering potential improvements in boron concentration within a tumor,” said Morrison. “These new compounds can deliver 2-3 times more boron across multiple cell lines and tumor models compared to BPA, potentially making BNCT more effective than ever imagined. We’re excited to share our early results at PTCOG 61.”
TAE Life Sciences will also have a poster presentation at PTCOG showcasing the technical details of its tandem-architecture neutron beam system for BNCT cancer treatment.
Bruce Bauer, CEO at TAE Life Sciences, expressed his enthusiasm about the future of BNCT, stating, “Our accelerator based Alphabeam technology for BNCT is now in active feasibility studies in Asia and closer than ever to reaching clinical trials in Europe and the Americas. We’re excited to share our progress towards realizing the potential of our groundbreaking Alphabeam system and boron delivery drug technologies with doctors and scientists who share our passion.”
TAE Life Sciences invites conference attendees and media representatives to attend Tuesday evening’s symposium to learn more about the latest BNCT device and drug innovations and breakthroughs. Food and beverages will be served.
About BNCT
BNCT is a combination treatment based on the reaction that occurs when a non-toxic compound containing boron-10 is irradiated with a low-energy neutron beam. BNCT differs radically from other radiation therapy and shows promise in becoming the next-generation cancer treatment. Research has shown BNCT has the capability of killing cancer cells that are resistant to traditional radiation therapy with limited harm to healthy tissue. Current advances in both neutron radiation technology and medicinal boron drug targeting are enabling BNCT’s potential to improve patient care while also improving treatment economics. To date, approximately 2,000 patients have been treated with BNCT at research sites worldwide.
About TAE Life Sciences
TAE Life Sciences is a privately held biotechnology company committed to developing a new biologically targeted radiation therapy based on Boron Neutron Capture Therapy (BNCT). TLS is developing the next generation targeted boron drugs and low-energy accelerator-based neutron source – optimized for an in-hospital BNCT program that can one day treat patients with the most aggressive and recurrent cancers. We have assembled a world-class, cross-functional team of clinicians, radiation oncologists, physicists, and other researchers to enable us to bring our technology to cancer patients who need it most. TLS’s target drugs and neutron radiation system are currently in development and have not been approved for sale. More information about TAE Life Sciences is available at www.taelifesciences.com.
